I'm LongbridgeAI, I can summarize articles.Twist Bioscience (TWST) added 2% this week to close at $127.22, outpacing the S&P 500 by roughly 2.8 percentage points against a 0.8% decline for the benchmark. The shortened four-session week started with a gap up and a spike to $131.60 on Tuesday before pulling back. Wednesday and Thursday closed at $125.52 and $126.85 respectively. Friday opened at $127.92, traded between $130.00 and $125.88, and settled at $127.22. Weekly amplitude was about 9.4%.
The Week
Twist Bioscience (TWST) added 2% this week to close at $127.22, outpacing the S&P 500 by roughly 2.8 percentage points against a 0.8% decline for the benchmark. The shortened four-session week started with a gap up and a spike to $131.60 on Tuesday before pulling back. Wednesday and Thursday closed at $125.52 and $126.85 respectively. Friday opened at $127.92, traded between $130.00 and $125.88, and settled at $127.22. Weekly amplitude was about 9.4%. The close sits below the 20-day moving average of $134.16 and above the 60-day average of $109.70.
Key Events
The story this week revolved around a management appearance and positioning moves. On 9 September, the company said its CEO and CFO would speak at a Baird Global Healthcare Conference fireside chat. The following day, media coverage highlighted the split between undervaluation on cash flow and overvaluation on sales for TWST, while Allianz Asset Management disclosed a new position in the stock. Broader market rotation themes, including Cathie Wood’s trades, also drew attention to synthetic DNA names, though Twist Bioscience itself had no major product, earnings, or regulatory update during the week.
Analyst Ratings
Across 13 firms covering the stock, 7 rate it buy, 2 rate it overweight, 3 rate it hold, and 1 rates it sell. The consensus recommendation is buy, with a consensus target of $106.25, about 16.5% below the current price. Targets range from $36.00 to $148.00, a wide spread. Within the biotechnology sector, the stock ranks 80th out of 506 companies by analyst rating.
The Week Ahead
A busy macro calendar is due next week. On 15 September, the New York Fed manufacturing index is scheduled (prior 20.6, forecast 14.75). On 16 September, retail sales (prior -0.6, forecast 0.9), retail sales ex-autos, retail control, import prices, the NAHB housing market index, and EIA crude inventories are all on tap. Company-specific catalysts remain light, with the Baird conference follow-through and any shifts in analyst targets as the main items to monitor.
In Short
TWST closed the week modestly higher and beat the broader market, even as mixed signals accumulated. Buy and overweight ratings make up the majority, yet the consensus target is about 16.5% below the latest price, and the target range spans roughly $112, pointing to wide dispersion. The most recent session’s flow showed some net selling from medium-sized orders. The next catalysts are management commentary after the Baird event and how next week’s macro data shapes risk appetite across biotech.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.